Mainz Biomed B.V. (MYNZ)
NASDAQ: MYNZ · IEX Real-Time Price · USD
0.750
-0.130 (-14.77%)
At close: May 1, 2024, 3:59 PM
0.785
+0.035 (4.67%)
After-hours: May 1, 2024, 7:52 PM EDT
Mainz Biomed B.V. Revenue
In the year 2023, Mainz Biomed B.V. had annual revenue of $895.48K with 69.00% growth. Revenue in the quarter ending December 31, 2023 was $214.76K with 11.11% year-over-year growth.
Revenue (ttm)
$895.48K
Revenue Growth
+69.00%
P/S Ratio
18.33
Revenue / Employee
$13,777
Employees
65
Market Cap
16.41M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 895.48K | 365.60K | 69.00% |
Dec 31, 2022 | 529.88K | -47.47K | -8.22% |
Dec 31, 2021 | 577.35K | 83.78K | 16.98% |
Dec 31, 2020 | 493.57K | 212.17K | 75.40% |
Dec 31, 2019 | 281.39K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
ATI Physical Therapy | 699.02M |
Aesthetic Medical International Holdings Group | 96.27M |
STRATA Skin Sciences | 33.36M |
Akso Health Group | 2.20M |
Talphera | 651.00K |
Benitec Biopharma | 61.00K |
QT Imaging Holdings | 40.36K |
MYNZ News
- 6 days ago - Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic - GlobeNewsWire
- 22 days ago - Mainz Biomed Reports Full Year 2023 Financial Results - GlobeNewsWire
- 6 weeks ago - Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment - GlobeNewsWire
- 6 weeks ago - Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options - GlobeNewsWire
- 7 weeks ago - Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations - GlobeNewsWire
- 2 months ago - Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic - GlobeNewsWire
- 2 months ago - Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community - GlobeNewsWire
- 2 months ago - Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert® - GlobeNewsWire